I. Juhan-vague

A. Evans, D. Arveiler, G. Luc, 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

Modulation of Adipose Tissue Development by Pharmacological Inhibition of PAI-1

D. L. Crandall, M. Alessi, I. Juhan-vague, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.

M. Alessi, P. Declerck, E. Kruithof, 1988, Blood.

Plasminogen Activator Inhibitor 1 and Atherothrombosis

M. Alessi, I. Juhan-vague, M. Alessi, 1993, Thrombosis and Haemostasis.

Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response.

P. Morange, M. Alessi, T. Cuisset, 2009, Thrombosis research.

Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels

P. Morange, J. Gris, M. Alessi, 2010, Journal of thrombosis and haemostasis : JTH.

Associations of Fibrinogen, Factor VII and PAI-1 with Baseline Findings among 10,500 Male Participants in a Prospective Study of Myocardial Infarction

A. Evans, D. Arveiler, G. Luc, 1998, Thrombosis and Haemostasis.

PAI-1, Obesity, and Insulin Resistance

P. Morange, M. Alessi, I. Juhan-vague, 1999 .

PAI-1 and the Risk of Cardiovascular Disease

M. Alessi, I. Juhan-vague, 1998 .

Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort.

G. Siest, D. Trégouët, L. Tiret, 1998, Arteriosclerosis, thrombosis, and vascular biology.

PAI-l AND THE RISK OF CARDIOVASCULAR DISEASE

M. Alessi, I. Juhan-vague, 1998 .

Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population.

D. Arveiler, F. Cambien, P. Amouyel, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1.

P. Vague, C. Atlan, I. Juhan-vague, 1987, Diabete & metabolisme.

Increased PA-Inhibitor Levels in the Postoperative Period – No Cause-Effect Relation with Increased Cortisol

M. Alessi, P. Vague, C. Arnaud, 1985, Thrombosis and Haemostasis.

Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis

M. Alessi, P. Holvoet, D. Collen, 1987, Thrombosis and Haemostasis.

Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases

I. Juhan-vague, M. Alessi, A. Mavri, 2004, Journal of internal medicine.

The A -844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers.

D. Trégouët, P. Morange, M. Alessi, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation

P. Morange, D. Bastelica, M. Alessi, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Haemostatic parameters and vascular risk

I. Juhan-vague, 1996 .

Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe

M. Margaglione, S. Humphries, E. Hawe, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Plasma TAFI Antigen Variations in Healthy Subjects

P. Morange, P. Chetaille, I. Juhan-vague, 2000, Thrombosis and Haemostasis.

Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors

P. Morange, M. Alessi, I. Juhan-vague, 2000, Arteriosclerosis, thrombosis, and vascular biology.

PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level.

P. Morange, G. Magalon, I. Juhan-vague, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus.

M. Alessi, P. Vague, I. Juhan-vague, 1996, Annals of medicine.

On the role of coagulation and fibrinolysis in atherosclerosis.

D. Collen, I. Juhan-vague, 1992, Annals of epidemiology.

Proteasome inhibition activates the transport and the ectodomain shedding of TNF-α receptors in human endothelial cells

I. Juhan-vague, D. Bernot, F. Peiretti, 2005, Journal of Cell Science.

Genetic Polymorphisms and Coronary Artery Disease in the South of France

L. Tiret, P. Morange, O. Poirier, 2000, Thrombosis and Haemostasis.

Plasminogen activator inhibitor-1, adipose tissue and insulin resistance

M. Poggi, M. Alessi, I. Juhan-vague, 2007, Current opinion in lipidology.

Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions.

D. Collen, I. Juhan-vague, M. Aillaud, 1984, Thrombosis research.

Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells.

I. Juhan-vague, F. Peiretti, S. Lopez, 2000, Atherosclerosis.

Biological and clinical features of low‐molecular‐weight heparin‐induced thrombocytopenia

Y. Gruel, P. Nguyên, J. Borg, 2003, British journal of haematology.

Adipose Tissue and Atherothrombosis

D. Bastelica, M. Alessi, H. Lijnen, 2003, Pathophysiology of Haemostasis and Thrombosis.

insulin and acute-phase response Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma

P. Vague, X. Thirion, P. Joly, 2011 .

CLINICAL RELEVANCE OF HIGH PAI-1 LEVEL IN PATIENTS WITH IDIOPATHIC/RECURRENT DEEP VENOUS THROMBOSIS

M. Alessi, I. Juhan-vague, A. Serradimigni, 1988 .

C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet

J. Tanti, C. Knauf, M. Iglesias, 2007, Diabetologia.

A 36 G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women

P. Morange, M. Poggi, D. Bastelica, 2018 .

Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort.

D. Tregouet, B. Balkau, P. Morange, 2011, Thrombosis and haemostasis.

ABDOMINAL OBESITY, INSULIN RESISTANCE, AND ALTERATIONS IN HEMOSTASIS

M. Alessi, I. Juhan-vague, F. D. Médecine, 2008 .

Results Effect of PAI-039 on PAI-1 Secretion by Preadipocytes : Basal

M. Alessi, I. Juhan-vague, E. Quinet, 2006 .

On the role of plasminogen activator inhibitor‐1 in adipose tissue development and insulin resistance in mice

D. Collen, H. Lijnen, I. Juhan-vague, 2005, Journal of thrombosis and haemostasis : JTH.

Hemostatic abnormalities associated with obesity and the metabolic syndrome

I. Juhan-vague, M. Alessi, 2005 .

In vitro inhibition of interleukin‐2‐induced defective polymorphonuclear chemotaxis by TNF inhibitor

D. Blaise, D. Maraninchi, I. Juhan-vague, 1993, European journal of haematology.

Plasminogen Activator Inhibitor Activity in Various Types of Endogenous Hypertriglyceridemia

D. Raccah, P. Vague, I. Juhan-vague, 1993 .

Associations of Fibrinogen, Factor VII and PAI 1 baseline findings among 10500 male participants in a prospective study of myocardial infarction a

A. Evans, D. Arveiler, G. Luc, 2018 .

Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing Plasminogen Activator Inhibitor-1

P. Morange, M. Alessi, H. Lijnen, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Stromal Cells Are the Main Plasminogen Activator Inhibitor‐1‐Producing Cells in Human Fat: Evidence of Differences Between Visceral and Subcutaneous Deposits

P. Morange, D. Bastelica, M. Alessi, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity.

P. Morange, D. Collen, M. Alessi, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue.

P. Morange, H. Lijnen, P. Vague, 1999, Diabetes.

Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women

D. Raccah, P. Vague, I. Juhan-vague, 1998, International Journal of Obesity.

Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women.

P. Vague, C. Atlan, I. Juhan-vague, 1989, Metabolism: clinical and experimental.

Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells.

M. Alessi, I. Juhan-vague, M. Alessi, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

Fibrinogen, fibrinolysis and diabetes mellitus: a comment

P. Vague, I. Juhan-vague, 1997, Diabetologia.

Fibrinolysis in insulin dependent diabetic patients with or without nephropathy

M. Alessi, D. Raccah, P. Vague, 1992 .

Hemobiology, vascular disease, and diabetes with special reference to impaired fibrinolysis.

D. Raccah, P. Vague, I. Juhan-vague, 1992, Metabolism: clinical and experimental.

Interrelations between carbohydrates, lipids, and the hemostatic system in relation to the risk of thrombotic and cardiovascular disease.

P. Vague, I. Juhan-vague, 1990, American journal of obstetrics and gynecology.

The increased plasma Lp(a): B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis.

M. Alessi, J. Fruchart, P. Joly, 1990, Clinica chimica acta; international journal of clinical chemistry.

Effect of 24 Hours of Normoglycaemia on Tissue-Type Plasminogen Activator Plasma Levels in Insulin Dependent Diabetes

P. Vague, C. Poisson, D. Collen, 1984, Thrombosis and Haemostasis.

Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay.

D. Collen, D. Rijken, I. Juhan-vague, 1983, The Journal of laboratory and clinical medicine.

Formation, Inhibition and Clearance of Plasmin in vivo

M. Alessi, W. Chandler, P. Vague, 2000, Pathophysiology of Haemostasis and Thrombosis.

Rapid Detection of Factor XIII Val34Leu by Allele Specific PCR

P. Morange, I. Juhan-vague, M. Alessi, 1999, Thrombosis and Haemostasis.

Five novel mutations located in exons III and IX of the protein C gene in patients presenting with defective protein C anticoagulant activity.

M. Aiach, P. Gaussem, S. Gandrille, 1993, Blood.

Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control.

J. Ansquer, C. Foucher, I. Juhan-vague, 2003, Atherosclerosis.

Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss

D. Bastelica, I. Juhan-vague, M. Alessi, 2001, Diabetologia.

Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothelial cells.

I. Juhan-vague, M. Alessi, G. Nalbone, 1993, Journal of lipid research.

Effect of low density lipoproteins on secretion of plasminogen activator inhibitor-1 (PAI-1) by human endothelial cells and hepatoma cells.

H. Portugal, M. Alessi, I. Juhan-vague, 1990 .

Plasminogen Activator Inhibitor-1 Expression in Human Liver and Healthy or Atherosclerotic Vessel Walls

M. Alessi, I. Juhan-vague, F. Anfosso, 1994, Thrombosis and Haemostasis.

ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome

P. Morange, M. Alessi, T. Cuisset, 2007, Thrombosis and Haemostasis.

Increase in Plasma Concentrationof Plasminogen Activator Inhibitor, Fibrinogen, von Willebrand Factor, Factor VIII: Cand in Erythrocyte Sedimentation Rate with Age

M. Alessi, J. Harlé, M. Escande, 1986, Thrombosis and Haemostasis.

Hypofibrinolysis and insulin-resistance.

P. Vague, I. Juhan-vague, 1991, Diabete & metabolisme.

Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study

R. Schnabel, S. Blankenberg, L. Tiret, 2007, Journal of thrombosis and haemostasis : JTH.

Effect of Atorvastatin on Plasminogen Activator Inhibitor Type‐1 Synthesis in Human Monocytes/Macrophages

I. Juhan-vague, F. Peiretti, S. Lopez, 2001, Journal of cardiovascular pharmacology.

Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity.

P. Morange, I. Juhan-vague, M. Alessi, 2000, Annals of medicine.

Contribution of PAI-1 in cardiovascular pathology.

I. Juhan-vague, M. Alessi, M. Alessi, 2004, Archives des maladies du coeur et des vaisseaux.

Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM.

J. Griffin, B. Jude, J. Abgrall, 1995, Blood.

Endothelial cell dysfunction in HIV infection.

C. Tamalet, C. Zandotti, I. Poizot-Martin, 1992, Journal of acquired immune deficiency syndromes.

Potentiation by Heparin Fragments of Thrombolysis Induced with Human Tissue-Type Plasminogen Activator or Human Single-Chain Urokinase-Type Plasminogen Activator

D. Collen, I. Juhan-vague, M. Alessi, 1987, Thrombosis and Haemostasis.

Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study

R. Schnabel, D. Tregouet, S. Blankenberg, 2009, Journal of thrombosis and haemostasis : JTH.

Assessment of D-dimer measurement by ELISA or latex methods in deep vein thrombosis diagnosed by ultrasonic duplex scanning

A. Elias, I. Juhan-vague, A. Serradimigni, 1990 .

Protein S deficiency and HIV infection.

C. Dhiver, I. Poizot-Martin, I. Juhan-vague, 1991, The New England journal of medicine.

Hyperactive polymorphonuclear leucocytes migration in patients with familial Mediterranean fever

P. Disdier, P. Weiller, I. Juhan-vague, 1996, Clinical Rheumatology.

Screening for identified and unidentified protein C pathway defects by the Agkistrodon contortrix venom test in consecutive patients.

P. Morange, I. Juhan-vague, M. Barthet, 1999, American journal of clinical pathology.

Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels.

P. Declerck, D. Collen, I. Juhan-vague, 1990, Thrombosis research.

MEASUREMENT OF PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) IN PLASMA WITH AN ELISA BASED ON TWO MURINE MONOCLONAL ANTIBODIES

P. Declerck, E. Kruithof, D. Collen, 1987 .

Fibrinolysis and Atherosclerosis

D. Collen, I. Juhan-vague, 1988, Seminars in thrombosis and hemostasis.

Weak and non‐independent association between plasma TAFI antigen levels and the insulin resistance syndrome

P. Morange, M. Alessi, C. Frère, 2003, Journal of thrombosis and haemostasis : JTH.

Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells

D. Raoult, M. Drancourt, I. Juhan-vague, 1990, Infection and immunity.

Tumor Necrosis Factor α Up-regulates in an Autocrine Manner the Synthesis of Plasminogen Activator Inhibitor Type-1 during Induction of Monocytic Differentiation of Human HL-60 Leukemia Cells*

I. Juhan-vague, F. Peiretti, S. Lopez, 2000, The Journal of Biological Chemistry.

Plasma Levels of Free and Total TFPI, Relationship with Cardiovascular Risk Factors and Endothelial Cell Markers

P. Morange, M. Charles, I. Juhan-vague, 2001, Thrombosis and Haemostasis.

[Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients)].

R. Khalil, L. Milandre, A. Elias, 1990, La Revue de medecine interne.

The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF alpha receptors.

M. Alessi, I. Juhan-vague, F. Peiretti, 2006, Atherosclerosis.

ABO Blood Group and Risk of Venous Thrombosis in Heterozygous Carriers of Factor V Leiden

I. Juhan-vague, M. Aillaud, V. Eschwège, 2000, Thrombosis and Haemostasis.

Modulation of PAI‐1 and proMMP‐9 syntheses by soluble TNFα and its receptors during differentiation of the human monocytic HL‐60 cell line

I. Juhan-vague, D. Bernot, F. Peiretti, 2003, Journal of cellular physiology.

Plasma Determination of Plasminogen Activator Inhibitor 1 Antigen Must Be Performed in Blood Collected on Antiplatelet/Anticoagulant Mixture

P. Declerck, E. Kruithof, I. Juhan-vague, 1987, Thrombosis and Haemostasis.

Functional consequences of the Ser334-->Pro mutation in a human factor X variant (factor XMarseille).

T. Miyata, H. Kato, I. Juhan-vague, 1995, European journal of biochemistry.

Circulating endothelial microparticles in malawian children with severe falciparum malaria complicated with coma.

M. Molyneux, J. Mege, T. Taylor, 2004, JAMA.

Acquired Protein S Deficiency, Likely due to Anti-PS Autoantibodies, following a Thrombotic Event in a Patient with a Systemic Lupus erythematosus

P. Morange, M. Alessi, J. Harlé, 1997, Thrombosis and Haemostasis.

New Direct Assay of Free Protein S Antigen Applied to Diagnosis of Protein S Deficiency

M. Alessi, J. Amiral, I. Juhan-vague, 1996, Thrombosis and Haemostasis.

The determination of functional plasminogen activator inhibitors (PAI) based on the inhibition of urokinase: PAI normal range and circadian variations in healthy donors; Comparison with other methods

M. Alessi, M. Aiach, P. Gaussem, 1990 .

Fibrinogen, obesity and insulin resistance.

P. Morange, I. Juhan-vague, M. Alessi, 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Increase in cytosolic calcium upregulates the synthesis of type 1 plasminogen activator inhibitor in the human histiocytic cell line U937

M. Alessi, I. Juhan-vague, F. Peiretti, 1996 .

Increase in cytosolic calcium upregulates the synthesis of type 1 plasminogen activator inhibitor in the human histiocytic cell line U937.

I. Juhan-vague, M. Alessi, F. Peiretti, 1996, Blood.

Anti‐phospholipid/cofactor antibodies in three cases of persistent polyclonal b lymphocytosis

R. Bouabdallah, M. Alessi, J. Serratrice, 2002, British journal of haematology.

Lupus anticoagulant in silica-induced scleroderma

M. Alessi, G. Kaplanski, I. Juhan-vague, 1992, Clinical Rheumatology.

Fat Cell Function and Fibrinolysis

P. Morange, I. Juhan-vague, M. Alessi, 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Regulation of Fibrinolysis in the Development of Atherothrombosis: Role of Adipose Tissue

I. Juhan-vague, M. Alessi, 1999, Thrombosis and Haemostasis.

Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach.

S. Heath, D. Trégouët, L. Tiret, 2009, Blood.

Factor XIIIV34L is not an additional genetic risk factor for venous thrombosis in Factor V Leiden carriers

P. Morange, I. Juhan-vague, D. Brunet, 2001 .

Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease

Alicja R. Rudnicka, Yoav Ben-Shlomo, Simon G. Thompson, 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome

P. Morange, M. Alessi, T. Cuisset, 2007, Thrombosis and Haemostasis.

Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma.

P. Declerck, D. Collen, I. Juhan-vague, 1991, Thrombosis research.

Detection of Plasminogen Activator Inhibitor-1 (PAI-1) mRNA in Human Megakaryocytes by In Situ Hybridization

I. Juhan-vague, M. Alessi, C. Fossat, 1994, Thrombosis and Haemostasis.

Comparison of the effects of aspirin and indomethacin on aortic atherogenesis induced in rabbits.

I. Juhan-vague, M. Aillaud, H. Payan, 1982, Atherosclerosis.

Possible participation of adenosine 5'-diphosphate, arachidonic acid and paf-acether in the platelet pro-aggregating effect of uncontrolled insulin-dependent diabetic erythrocytes in vitro.

M. Chignard, P. Vague, J. Benveniste, 1985, Thrombosis research.

Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay.

D. Collen, D. Rijken, I. Juhan-vague, 1983, The Journal of laboratory and clinical medicine.

Treatment of deep vein thrombosis with a very low molecular weight heparin (CY 222 - Choay): Thrombolysis and plasma fibrinolytic parameters

M. Alessi, A. Elias, I. Juhan-vague, 1988 .

Up-Regulated Expression of Plasminogen Activator Inhibitor-1 in Hep G2 Cells: Interrelationship between Insulin and Insulin-Like Growth Factor 1

M. Alessi, I. Juhan-vague, G. Nalbone, 1995, Thrombosis and Haemostasis.

The Effect of Metformin on the Metabolic Abnormalities Associated With Upper-Body Fat Distribution. BIGPRO Study Group

M. Safar, A. Fontbonne, M. Charles, 1996, Diabetes Care.

Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects.

M. Alessi, P. Vague, D. Collen, 1986, Metabolism: clinical and experimental.

Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study

P. Morange, I. Juhan-vague, 2003, Journal of thrombosis and haemostasis : JTH.

Fluvastatin Decreases Soluble Thrombomodulin in Cardiac Transplant Recipients

G. Habib, G. Bouvenot, I. Juhan-vague, 2000, Thrombosis and Haemostasis.

Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence

A. Evans, D. Arveiler, G. Luc, 2003, Thrombosis and Haemostasis.

Clinical Features in 36 Patients Homozygous for the ARG 506 → GLN Factor V Mutation

B. Jude, J. Emmerich, J. Fiessinger, 1997, Thrombosis and Haemostasis.

Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact

D. Tregouet, P. Morange, M. Alessi, 2005, Thrombosis and Haemostasis.

The Fibrinolytic System and Obesity

H. Lijnen, I. Juhan-vague, 2002, Thrombosis and Haemostasis.

Pathophysiology of fibrinolysis.

P. Declerck, I. Juhan-vague, M. Alessi, 1995, Bailliere's Clinical Haematology.

A 13 base pair deletion in the GPIbβ gene in a second unrelated Bernard–Soulier family due to slipped mispairing between direct repeats

I. Juhan-vague, M. Alessi, F. Lanza, 2004, Journal of thrombosis and haemostasis : JTH.

Pathophysiology of fibrinolysis

Jordi Félez, P. Declerck, I. Juhan-vague, 1994, Journal of internal medicine.

TGF-β1 Released from Activated Platelets Can Induce TNF-Stimulated Human Brain Endothelium Apoptosis: A New Mechanism for Microvascular Lesion during Cerebral Malaria1

G. Grau, I. Juhan-vague, Corinne Frère, 2006, The Journal of Immunology.

Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states.

D. Raccah, P. Vague, I. Juhan-vague, 1992, Diabete & metabolisme.

Title Page / Table of Contents / Preface

F. Sofi, R. Abbate, P. Morange, 2003, Pathophysiology of Haemostasis and Thrombosis.

« Hémophilie acquisepar anticorps antifacteur VIII c: A propos de 3 observations

R. Gola, P. Weiller, I. Juhan-vague, 1983 .

[Disseminated intravascular coagulation masking neonatal hemophilia].

I. Juhan-vague, J. Guys, J. Camboulives, 1991, Annales de pediatrie.

Intracellular calcium mobilization suppresses the TNF-alpha-stimulated synthesis of PAI-1 in human endothelial cells. Indications that calcium acts at a translational level.

M. Alessi, I. Juhan-vague, F. Peiretti, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME Study

D. Arveiler, G. Luc, J. Ruidavets, 2000, Journal of Human Hypertension.

Systematically missing confounders in individual participant data meta-analysis of observational cohort studies

H Tunstall-Pedoe, Dan Jackson, S G Thompson, 2009, Statistics in medicine.

Correction by insulin added in vitro of abnormal membrane fluidity of the erythrocytes from Type 1 (insulin-dependent) diabetic patients

P. Vague, I. Juhan-vague, M. Aillaud, 1986, Diabetologia.

Effects of DDAVP and venous occlusion on the release of tissue-type plasminogen activator and von Willebrand factor in patients with panhypopituitarism.

D. Collen, I. Juhan-vague, M. Aillaud, 1984, Thrombosis research.

Platelets Potentiate Brain Endothelial Alterations Induced by Plasmodium falciparum

G. Grau, I. Juhan-vague, V. Combes, 2006, Infection and Immunity.

p38 mitogen activated protein kinase controls two successive-steps during the early mesodermal commitment of embryonic stem cells.

D. Nègre, V. Renault, B. Binétruy, 2011, Stem cells and development.

Exclusive expression of transmembrane TNF-α in mice reduces the inflammatory response in early lipid lesions of aortic sinus

P. Morange, H. Portugal, I. Juhan-vague, 2004 .

Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities.

S. Thompson, M. Alessi, J. Jespersen, 1996, Circulation.

Fibrinolytic function and coronary risk

P. Morange, I. Juhan-vague, Marie Christine Alessi, 1999, Current cardiology reports.

Overexpression of PAI-1 Does Not Affect Adipose Tissue Development in Mice on SFD

P. Morange, M. Alessi, D. Collen, 2002 .

Platelet antibodies in Mediterranean tick typhus.

D. Raoult, P. Weiller, I. Juhan-vague, 1985, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis.

Y. Berland, P. Brunet, B. Dussol, 1995, Kidney international.

Plasma Plasminogen Activator Inhibitor‐1 in Angina Pectoris: Influence of Plasma Insulin and Acute‐phase Response

M. Alessi, P. Declerck, P. Vague, 1989, Arteriosclerosis.

Relevance of Free tPA Assay Following Venous Occlusion in Patients with Venous Thromboembolic Disease

P. Holvoet, D. Collen, I. Juhan-vague, 1988, Thrombosis and Haemostasis.

Binding of 99mTc Plasminogen on Fibrin

F. Roux, I. Juhan-vague, A. Serradimigni, 1981, Thrombosis and Haemostasis.

Fibrinolytic activity in experimental vascular grafts.

I. Juhan-vague, M. Aillaud, C. Juhan, 1983, Haemostasis.

Insulin Stimulates the Synthesis of Plasminogen Activator Inhibitor 1 by the Human Hepatocellular Cell Line Hep G2

T. Kooistra, P. Declerck, D. Collen, 1988, Thrombosis and Haemostasis.

Measurement of Low Molecular Weight Heparin Ex Vivo Activities in Clinical Laboratories Using Various Anti-Xa Assays: Interlaboratory Variability and Requirement for an Agreed Low Molecular Weight Heparin Standard

B. Polack, M. Aiach, I. Juhan-vague, 1987, Thrombosis and Haemostasis.

Protein Z plasma levels are not associated with the risk of coronary heart disease: the PRIME Study

P. Morange, I. Juhan-vague, 2004, Journal of thrombosis and haemostasis : JTH.

Inhibition of p70S6 Kinase during Transforming Growth Factor-β1/Vitamin D3-induced Monocyte Differentiation of HL-60 Cells Allows Tumor Necrosis Factor-α to Stimulate Plasminogen Activator Inhibitor-1 Synthesis*

I. Juhan-vague, F. Peiretti, S. Lopez, 2001, The Journal of Biological Chemistry.

Lupus anticoagulants and antiphospholipid antibodies: comparison of clotting tests with an immunological assay.

M. Alessi, J. Harlé, J. Amiral, 1990, Thrombosis research.

In vivo stimulation of neutrophil function by lenograstim (glycosylated rHug‐CSF) in oncohematologic patients: Results of a phase I trial

D. Blaise, P. Viens, A. Yver, 1994, Stem cells.

Bivariate familial correlation analysis of quantitative traits by use of estimating equations: Application to a familial analysis of the insulin resistance syndrome

G. Siest, D. Trégouët, L. Tiret, 1999, Genetic epidemiology.

Cutaneous Necrosis Associated with Acquired Severe Protein S Deficiency

M. Alessi, I. Juhan-vague, M. Aillaud, 1993, Thrombosis and Haemostasis.

ABCA1 gene deletion protects against cerebral malaria: potential pathogenic role of microparticles in neuropathology.

G. Grau, G. Chimini, I. Juhan-vague, 2005, The American journal of pathology.

Antibodies to Phosphatidylethanolamine as the only Antiphospholipid Antibodies Found in Patients with Unexplained Thromboses

M. Alessi, J. Harlé, P. Weiller, 2001, Thrombosis and Haemostasis.

Association of a sequence variant in DAB2IP with coronary heart disease

M. Margaglione, S. Humphries, A. Neil, 2011, European heart journal.

Activation of Plasminogen Activator Inhibitor-1 Synthesis by Phorbol Esters in Human Promyelocyte HL-60

E. Huberman, I. Juhan-vague, F. Peiretti, 1999, Thrombosis and Haemostasis.

Platelet microparticles: a new player in malaria parasite cytoadherence to human brain endothelium

M. Alessi, A. Fontaine, T. Fusaï, 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Metabolic syndrome, haemostasis and thrombosis

M. Alessi, I. Juhan-vague, 2008, Thrombosis and Haemostasis.

PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences

M. Alessi, I. Juhan-vague, 2006, Arteriosclerosis, thrombosis, and vascular biology.

EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro.

J S Yudkin, A H Goodall, D J Stearns-Kurosawa, 2005, Atherosclerosis.

Plasminogen activator inhibitor‐1, inflammation, obesity, insulin resistance and vascular risk

P. Morange, I. Juhan-vague, M. Alessi, 2003, Journal of thrombosis and haemostasis : JTH.

The Medi-RIVAGE study (Mediterranean Diet, Cardiovascular Risks and Gene Polymorphisms): rationale, recruitment, design, dietary intervention and baseline characteristics of participants

A. Loundou, D. Lairon, H. Portugal, 2004, Public Health Nutrition.

Comparison of skin microvascular reactivity with hemostatic markers of endothelial dysfunction and damage in type 2 diabetes

L. Liaudet, B. Waeber, J. Ruiz, 2008, Vascular health and risk management.

Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study

M. Margaglione, S. Humphries, D. Tregouet, 2007, Arteriosclerosis, thrombosis, and vascular biology.

Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group.

S. Thompson, J. Jespersen, I. Juhan-vague, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled.

L. Tiret, P. Morange, M. Alessi, 2001, Blood.

Characterization of Epitheloid Cells from Human Omentum: Comparison with Endothelial Cells from Umbilical Veins

M. Alessi, I. Juhan-vague, F. Anfosso, 1991, Thrombosis and Haemostasis.

The shedding activity of ADAM17 is sequestered in lipid rafts.

I. Juhan-vague, F. Peiretti, B. Bonardo, 2006, Experimental cell research.

FHL2 interacts with both ADAM‐17 and the cytoskeleton and regulates ADAM‐17 localization and activity

M. Aumailley, I. Juhan-vague, F. Peiretti, 2006, Journal of cellular physiology.

Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study.

D. Tregouet, L. Tiret, P. Morange, 2006, Blood.

Ala147Thr and C+1542G Polymorphisms in the TAFI Gene Are not Asssociated with a Higher Risk of Venous Thrombosis in FV Leiden Carriers

P. Morange, V. Nicaud, I. Juhan-vague, 2001, Thrombosis and Haemostasis.

Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study.

A. Evans, D. Arveiler, G. Luc, 2008, European heart journal.

Contributions of Depressive Mood and Circulating Inflammatory Markers to Coronary Heart Disease in Healthy European Men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME)

X. Jouven, A. Evans, D. Arveiler, 2005, Circulation.

Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe

M. Margaglione, S. Humphries, E. Hawe, 2004, Thrombosis and Haemostasis.

C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart Disease: The PRIME Study

A. Evans, D. Arveiler, G. Luc, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Identification of SAP97 as an intracellular binding partner of TACE

I. Juhan-vague, F. Peiretti, B. Bonardo, 2003, Journal of Cell Science.

Acquired inhibitor of thrombin associated with an ulcerative colitis

P. Morange, J. Serratrice, P. Disdier, 2000, American journal of hematology.

The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency.

M. Aiach, D. Borgel, S. Gandrille, 1995, Blood.

Accumulation of Triglyceride-Rich Lipoprotein in Subjects With Abdominal Obesity: The Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 Study

M. Safar, M. Charles, J. Fruchart, 2001, Arteriosclerosis, thrombosis, and vascular biology.

Tissue-type plasminogen activator antigen (t-PA Ag)

I. Juhan-vague, M. Alessi, 1992 .

Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.

P. Morange, M. Alessi, T. Cuisset, 2008, The American journal of cardiology.

Plasma fibrinogen concentration predicts the risk of myocardial infarction differently in various parts of Europe: effects of β-fibrinogen genotype and environmental factors

M. Margaglione, S. Humphries, E. Hawe, 2004, Thrombosis and Haemostasis.

Daytime Fluctuations of Plasminogen Activator Inhibitor 1 (PAI-1) in Populations with High PAI-1 Levels

D. Raccah, P. Vague, I. Juhan-vague, 1992, Thrombosis and Haemostasis.

Relationships between alcoholic beverages and cardiovascular risk factor levels in middle-aged men, the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction Study.

D. Arveiler, G. Luc, J. Ruidavets, 2001, Atherosclerosis.

Development of a Genotype 325–Specific proCPU/TAFI ELISA

Els Brouwers, Ann Gils, A. Gils, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Blood Coagulation, Fibrinolysis and Cellular Haemostasis Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus Results from the D.E.S.I.R. prospective cohort

D. Tregouet, B. Balkau, P. Morange, 2017 .

Relation between Plasma PAI Activity and Adipsin Levels

M. Alessi, P. Vague, I. Juhan-vague, 1995, Thrombosis and Haemostasis.

Proinflammatory properties of murine aortic endothelial cells exclusively expressing a non cleavable form of TNFα

I. Juhan-vague, D. Bernot, F. Peiretti, 2004, Thrombosis and Haemostasis.

Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study

D. Arveiler, G. Luc, P. Amouyel, 2010, International Journal of Obesity.

Hemostatic Abnormalities in Diabetes

P. Morange, M. Alessi, I. Juhan-vague, 2003 .

Relationships between Fibrinolytic and Inflammatory Parameters in Human Adipose Tissue: Strong Contribution of TNFα Receptors to PAI-1 Levels

D. Bastelica, M. Alessi, I. Juhan-vague, 2002, Thrombosis and Haemostasis.

The insulin resistance syndrome: implications for thrombosis and cardiovascular disease

P. Morange, M. Alessi, I. Juhan-vague, 2002, Pathophysiology of Haemostasis and Thrombosis.

Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity.

P. Morange, D. Bastelica, M. Alessi, 2000, Diabetes.

Variables of the fibrinolytic system: risk indicators for CHD

M. Alessi, I. Juhan-vague, 1997 .

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

M. Alessi, P. Vague, I. Juhan-vague, 1991, Diabetologia.

Venous Occlusion Does Not Induce the Release of Thrombomodulin from Endothelial Cells in Patients with Thromboembolic Disease

M. Alessi, I. Juhan-vague, C. Menart, 1992, Thrombosis and Haemostasis.

Effect of diet-induced weight loss on endothelial dysfunction: early improvement after the first week of dieting

I. Juhan-vague, P. Poredos, B. Gaborit, 2010, Heart and Vessels.

Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women

P. Morange, M. Poggi, D. Bastelica, 2006, Thrombosis and Haemostasis.

PLASMA HISTIDINE-RICH GLYCOPROTEIN AND THROMBOPHILIA

C. Kluft, E. Briët, I. Juhan-vague, 1988 .

TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study

D. Arveiler, G. Luc, L. Tiret, 2004, European Journal of Human Genetics.

Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity.

P. Morange, M. Charles, P. Vague, 1998, Diabetes care.

[The link between molecules produced by the adipose tissue, obesity and atherothrombosis].

M. Alessi, C. Frère, I. Juhan-vague, 2005, Presse medicale.

Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study.

M. Margaglione, S. Humphries, E. Hawe, 2004, Metabolism: clinical and experimental.

Chronic plasminogen activator inhibitor‐1 (PAI‐1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung

M. Poggi, D. Bastelica, M. Alessi, 2007, Journal of thrombosis and haemostasis : JTH.

Purpura Fulminans in a Patient Homozygous for a Mutation in the Protein C Gene - Prenatal Diagnosis in a Subsequent Pregnancy

M. Alessi, I. Juhan-vague, B. Roquelaure, 1996, Thrombosis and Haemostasis.

Plasma cystatin-C and development of coronary heart disease: The PRIME Study.

A. Evans, D. Arveiler, G. Luc, 2006, Atherosclerosis.

Catastrophic Arterial Reactivity During Primary Antiphospholipid Syndrome

P. Morange, J. Serratrice, P. Disdier, 1999, Angiology.

Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms

D. Tregouet, L. Tiret, P. Morange, 2001, Human Genetics.

Plasmodium falciparum rhoptry protein RSP2 triggers destruction of the erythroid lineage.

I. Juhan-vague, F. T. Costa, P. Nogueira, 2005, Blood.

Prospective analysis of factor XI deficiencies in the Marseilles area identified four novel mutations among 12 consecutive unrelated families

P. Morange, P. de Mazancourt, C. Frère, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

activatable fibrinolysis inhibitor antigen levels by a trans-ethnic study Fine mapping of quantitative trait nucleotides underlying thrombin

D. Trégouët, L. Tiret, P. Morange, 2013 .

Thr325IIe polymorphism of the TAFI gene does not influence the risk of myocardial infarction.

P. Morange, I. Juhan-vague, C. Frere, 2002, Blood.

U937 plasminogen activator inhibitor in the human histiocytic cell line Increase in cytosolic calcium upregulates the synthesis of type 1

I. Juhan-vague, M. Alessi, F. Peiretti, 2011 .

Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study

D. Tregouet, S. Blankenberg, D. Trégouët, 2008, Journal of Molecular Medicine.

[Cerebral phlebitis and Crohn disease].

R. Khalil, L. Milandre, I. Juhan-vague, 1992, Revue neurologique.

Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study.

M. Margaglione, S. Humphries, E. Hawe, 2005, Atherosclerosis.

Measures to assess the prognostic ability of the stratified Cox proportional hazards model

Alicja R. Rudnicka, Mark Woodward, Yoav Ben-Shlomo, 2009, Statistics in medicine.

Tiplaxtinin impairs nutritionally induced obesity in mice

M. Alessi, H. Lijnen, D. Collen, 2006, Thrombosis and Haemostasis.

Adipose Tissue Expression of Gelatinases in Mouse Models of Obesity

P. Morange, H. Lijnen, A. Mertens, 2001, Thrombosis and Haemostasis.

Federal autonomy and the politics of reform: the standardization of mortality statistics in Germany c.1850-1914.

R. Glass, S. Awasthi, J. Mege, 2001 .

TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study

D. Tregouet, D. Arveiler, G. Luc, 2005, Journal of thrombosis and haemostasis : JTH.

Molecular characterization of a novel mutation in the factor XIII a subunit gene associated with a severe defect: importance of prophylactic substitution.

P. Morange, C. Boucly, P. de Mazancourt, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Insulin resistance and alterations in the fibrinolytic system

I. Juhan-vague, Gough Scl., 1993 .

Upregulation of TNF-alpha-induced ICAM-1 surface expression by adenylate cyclase-dependent pathway in human endothelial cells.

I. Juhan-vague, D. Bernot, F. Peiretti, 2005, Journal of cellular physiology.

Activation of coagulation in decompression illness.

A. Boussuges, J. Sainty, I. Juhan-vague, 1998, Aviation, space, and environmental medicine.

Iloprost and salvage of a free flap.

I. Juhan-vague, M. Alessi, R. Legré, 1996, British Journal of Plastic Surgery.

[Septicemia, portal thrombosis and congenital protein C deficiency].

P. Devred, J. Garnier, I. Juhan-vague, 1988, Archives francaises de pediatrie.

Natural inhibitors of fibrinolysis.

I. Juhan-vague, A. Serradimigni, M. Aillaud, 1986, Haemostasis.

Plasma Plasminogen Activator Inhibitor Activity in Rats with Nutritionally Induced Insulin Resistance

M. Alessi, D. Raccah, P. Vague, 1995, Thrombosis and Haemostasis.

PPARα deficiency does not modify age dependency but prevents high fat diet increase in plasma PAI-1 as well as insulin resistance

D. Bastelica, M. Alessi, B. Staels, 2004, Thrombosis and Haemostasis.

Fibrinolysis and atherothrombosis

M. Alessi, I. Juhan-vague, G. Nalbone, 1993 .

Plasma reactivity to hexagonal II phase phosphatidylethanolamine is more frequently associated with lupus anticoagulant than with antiphosphatidylethanolamine antibodies.

J. Piette, J. Harlé, P. Cacoub, 1993, The Journal of laboratory and clinical medicine.

Released from Activated Platelets Can Induce TNF-Stimulated Human Brain Endothelium Apoptosis: A New Mechanism for Microvascular Lesion during Cerebral Malaria

E. Georges, I. Juhan-vague, Corinne Frère, 2005 .

Treatment with metformin of non‐diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial

E. Eschwège, P. Vague, I. Juhan-vague, 2000, Diabetes/metabolism research and reviews.

Protein S deficiency: different biological phenotypes according to the assays used.

P. Morange, M. Alessi, D. Borgel, 1998, Thrombosis and haemostasis.

Specificity of an Assay Based on a Factor V-depleted Plasma in Patients Carrying the Arg 506 GIn Mutation

M. Aiach, I. Juhan-vague, M. Aillaud, 1996, Thrombosis and Haemostasis.

A Three-generation Family Presenting Five Cases of Homozygosity for the 20210 G to A Prothrombin Variant

P. Morange, M. Alessi, I. Juhan-vague, 1998, Thrombosis and Haemostasis.

Polymorphisms of the lamina maturation pathway and their association with the metabolic syndrome: the DESIR prospective study

D. Trégouët, P. Morange, M. Marre, 2010, Journal of Molecular Medicine.

Resistance to Activated Protein C – Diagnostic Strategy in a Laboratory of Haemostasis

P. Gallian, P. Morange, M. Alessi, 1995, Thrombosis and Haemostasis.

A novel missense mutation shows that GPIbbeta has a dual role in controlling the processing and stability of the platelet GPIb-IX adhesion receptor.

P. Nurden, M. Alessi, H. Chambost, 2003, Biochemistry.

Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort.

D. Trégouët, B. Balkau, O. Lantieri, 2011 .

Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.

M. Alessi, P. Declerck, E. Kruithof, 1988, Blood.

Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study

D. Trégouët, E. Lubos, C. Bickel, 2009, Journal of thrombosis and haemostasis : JTH.

Correction by pentoxifylline of the abnormal fluorescence polarization of erythrocyte membranes from diabetic patients

P. Vague, I. Juhan-vague, Z. Mishal, 2004, European Journal of Clinical Pharmacology.

The effect of plasma proteins and glycosylated fibrinogen on red blood cell aggregation in diabetes

J. Soria, C. Soria, P. Vague, 1991 .

Treatment of Venous Thrombosis and Pulmonary Embolism by Streptokinase

I. Juhan-vague, P. Djiane, A. Serradimigni, 1978, Angiology.

[Immunologic determination of the protein C of coagulation: detection of deficiencies].

J. Amiral, I. Juhan-vague, M. Aillaud, 1985, Annales de biologie clinique.